Mesh Bio, a health deep tech startup, secured investment from East Ventures

Mesh Bio, a Singapore-based health deep tech startup in transforming chronic disease management through predictive analytics, announced that it had raised an undisclosed amount of funding from East Ventures, a pioneering and leading sector-agnostic venture capital firm focusing on Southeast Asia. The funding will be allocated to further develop the digital twin technologies in chronic disease management and to expand its services across Southeast Asia, mainly Indonesia, Malaysia, and the Philippines. 

“Given the increasing aging population worldwide, Mesh Bio has consistently prioritized the development of innovative solutions to alleviate healthcare challenges associated with chronic diseases. We are glad to receive the support from East Ventures, and we are confident that this funding will serve as a strong foundation in our vision to confront the rising burden of chronic diseases across the regions,” said Dr. Andrew Wu, Co-Founder and Chief Executive Officer of Mesh Bio.

Founded in 2018 by Andrew Wu (Co-Founder and Chief Executive Officer) and Arsen Batagov (Co-Founder and Chief Technology Officer), Mesh Bio has the vision to deliver cutting-edge digital solutions to address challenges in patient management and rising chronic diseases in the region. 

Noncommunicable diseases (NCDs) or chronic diseases, such as cardiovascular diseases and diabetes, impose a major and growing burden on health and development in the Southeast Asia region. In the region, 62% of all deaths are due to NCDs, accounting for 9 million persons.

The increase in chronic diseases leads to complex and challenging patient management. The situation is compounded by the lack of doctors, especially specialists, so that general practitioners who lack specialist training in endocrinology are forced to manage these challenging patient cases.

Mesh Bio presents cutting-edge digital solutions to address challenges in patient management and rising chronic diseases in the region. Mesh Bio’s Health Intelligence Platform, named DARA®, provides real-time, multidimensional patient data, which includes health history, lab tests, and medical images. DARA® delivers a patient-centric visual report, helping doctors counsel patients and allowing patients to understand their laboratory reports and the diseases they live with.

Based on the data, DARA® provides predictive analytics to identify patients at risk of chronic diseases for earlier diagnosis and treatment. Moreover, DARA® also enables doctors to leverage knowledge from the global community of healthcare practitioners according to clinical best practices, guidelines, and holistic patient assessments. 

“Mesh Bio’s innovative approach and cutting-edge technology could potentially become one of the foundations to provide a better healthcare system for the region. We believe that predictive analytics and preventive healthcare can provide many potential benefits for society, and we believe that Mesh Bio will lead this revolution with its digital twin engine. We are excited to welcome Mesh Bio to East Ventures’ ecosystem,” said Willson Cuaca, Co-Founder and Managing Partner at East Ventures.